Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset From Bridge Medicines
Galecto完成戰略審查,專注於腫瘤學和肝臟疾病,並從Bridge Medicines收購急性髓性白血病臨床前資產
Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset From Bridge Medicines
Galecto完成戰略審查,專注於腫瘤學和肝臟疾病,並從Bridge Medicines收購急性髓性白血病臨床前資產
譯文內容由第三人軟體翻譯。